Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan

References

• Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138. doi:10.1016/j.jaci.2007.09.043.[published Online First: 2007/12/06]
   PubMed Web of Science ®Google Scholar
• Ichinose M, Sugiura H, Nagase H, Yamaguchi M, Inoue H, Sagara H, Tamaoki J, Tohda Y, Munakata M, Yamauchi K, et al. Japanese guidelines for adult asthma 2017. Allergol Int. 2017;66(2):163–189. doi:10.1016/j.alit.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Sato K, Ohno T, Ishii T, Ito C, Kaise T. The prevalence, characteristics, and patient burden of severe asthma determined by using a Japan health care claims database. Clin Ther. 2019;41(11):2239–2251. doi:10.1016/j.clinthera.2019.08.015.
   PubMed Web of Science ®Google Scholar
• Sanofi/Regeneron Global Brand Team. Asthma Brand Plan 2018. 2017.
   Google Scholar
• Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: A novel treatment for asthma. J Asthma Allergy. 2014;7:123–130. doi:10.2147/jaa.s52387.
   PubMedGoogle Scholar
• Nagase H. Severe asthma in Japan. Allergol Int. 2019;68(2):167–171. doi:10.1016/j.alit.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Wu AC, Fuhlbrigge AL, Robayo MA, Shaker M. Cost-effectiveness of biologics for allergic diseases. J Allergy Clin Immunol Pract. 2021;9(3):1107–1117. doi:10.1016/j.jaip.2020.10.009.[published Online First: 2020/10/19]
   PubMed Web of Science ®Google Scholar
• Anderson WC, III, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372. doi:10.1016/j.anai.2019.01.018. [published Online First: 2019/02/01]
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1058–1068. doi:10.1111/all.14268. [published Online First: 2020/03/11]
   PubMed Web of Science ®Google Scholar
• Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36. doi:10.1016/j.vhri.2013.01.007. [published Online First: 2013/05/01]
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]. London, UK: National Institute for Health and Care Excellence; 2016 Nov [accessed 2019 Oct 10]. https://www.nice.org.uk/guidance/ta479/documents/committee-papers-4.
   Google Scholar
• Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig. 2012;32(4):253–265. doi:10.2165/11598940-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: A systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 2013;17(52):1–342. doi:10.3310/hta17520.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Mepolizumab for treating severe eosinophilic asthma [ID798]. London, UK: National Institute for Health and Care Excellence; 2017 Jan [accessed 2019 October 10]. https://www.nice.org.uk/guidance/ta431.
   Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410–418. [published Online First: 2013/01/30] doi:10.3109/02770903.2013.767909.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health. 2017;20(3):372–378. [published Online First: 2017/03/16] doi:10.1016/j.jval.2016.08.726.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x. [published Online First: 2005/02/01]
   PubMed Web of Science ®Google Scholar
• Bateman ED, Khan AH, Xu Y, Guyot P, Chao J, Kamat S, Rowe P, Burnett H, Msihid J, Weinreich D, et al. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respir Med. 2020:105991. doi:10.1016/j.rmed.2020.105991.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Mepolizumab for treating severe refractory eosinophilic asthma in adults [ID798]. Company response to the second ACD. London, UK: National Institute for Health and Care Excellence; 2016 Aug [accessed 2019 Oct 10]. https://www.nice.org.uk/guidance/ta431/documents/committee-papers.
   Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, Chang S-C, Kuhlbusch K, Heaney LG, Jick SS, Meier CR. Adverse events profile of oral corticosteroids among asthma patients in the UK: Cohort study with a nested case–control analysis. Respir Res. 2018;19(1):75. [published Online First: 2018/04/28]. doi:10.1186/s12931-018-0742-y.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labor and Welfare. The 22nd life tables. Tokyo, Japan: Ministry of Health, Labor and Welfare [accessed 2019 Oct 10]. https://www.mhlw.go.jp/english/database/db-hw/lifetb22nd/index.html.
   Google Scholar
• Zafari Z, Sadatsafavi M, Mark FitzGerald J for the Canadian Respiratory Research Network. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Res Alloc. 2018;16(1):3. [published Online First: 2018/02/10] doi:10.1186/s12962-018-0089-8.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Benralizumab for treating severe eosinophilic asthma [TA565]. London, UK: National Institute for Health and Care Excellence; 2019 Sep [accessed 2019 Oct 10]. https://www.nice.org.uk/guidance/ta565.
   Google Scholar
• Ministry of Health, Labor and Welfare. Drug Master Search. Various information on medical fees. Tokyo, Japan: Ministry of Health, Labor and Welfare [accessed 2018 Apr]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000078916.html.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Search of package inserts. Tokyo, Japan: Pharmaceuticals and Medical Devices Agency [accessed 2019 Oct 10]. http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html.
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108. doi:10.1097/00005650-199711000-00002. [published Online First: 1997/11/21]
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. [published Online First: 2012/08/08] doi:10.1016/j.jval.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804. [published Online First: 2011/03/23] doi:10.1177/0272989X11401031.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic corticosteroids. Qual Life Res. 2017;26(4):1037–1058. [published Online First: 2016/10/21] doi:10.1007/s11136-016-1435-y.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: A unique health technology assessment system. Value Health. 2020;23(1):43–51. doi:10.1016/j.jval.2019.10.005.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: A systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–971. doi:10.1007/s40273-018-0658-x.
   PubMed Web of Science ®Google Scholar
• Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-naïve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2020;38(1):69–84. doi:10.1007/s40273-019-00841-1. [published Online First: 2019/09/26]
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019;54(6):558–570. doi:10.1007/s00535-019-01554-0. [published Online First: 2019/02/23]
   PubMed Web of Science ®Google Scholar
• Sakamaki H, Nakao K, Matsumoto T, Inoue S. Cost-effectiveness analysis of percutaneous mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation in Japan. J Med Econ. 2019;22(12):1312–1320. doi:10.1080/13696998.2019.1668132.
   PubMed Web of Science ®Google Scholar